A randomized study of subconjonctival bevacizumab (Avastin ®) injection for corneal neovascularization

CONCLUSION: This study shows the efficacy of subconjunctival bevacizumab injection in the reduction of neovascularized corneal surface area versus placebo, but only when the neovascularization has been present less than 1year. Nevertheless, the study did not attain the statistical power to pass the threshold of significance.PMID:38696862 | DOI:10.1016/j.jfo.2024.104152
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Authors: Source Type: research